SEC For	m 4																	
FORM 4 UI			UNITED S	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					AT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							HIP	Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person [*] BELANOFF JOSEPH K					2. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC</u> [CORT]							CK all applica	able)	, 10% Ov		ner		
(Last)(First)(Middle)C/O CORCEPT THERAPEUTICSINCORP149 COMMONWEALTH DRIVE				ED 0	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2021								Chief Executive Officer					
(Street) MENLO PARK CA 94025				4. 	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Lir								Individual or Joint/Group Filing (Check Applicable ie) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						2A. Deemed Execution Date, if any (Month/Day/Year)		ar) 8)	str.		tr. 3, 4 and 9	Beneficia Owned Fo Reported	ly (D) or llowing (I) (In		: Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/)	ate	and 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)					
Stock Option (Right to Buy)	\$29.41	02/05/2021		A		500,000		(1)	02/04/2031	Common Stock	500,000	\$0.00	500,000		D			

Explanation of Responses:

1. Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 5, 2021, so that the total number of shares subject to this option becomes fully vested and exercisable on February 5, 2025.

Remarks:

/s/ Gary Charles Robb, Attorney-in-Fact for Joseph K.

02/08/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.